SIKANDER AILAWADHI, MD

Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l

New patient office or other outpatient visit, 60-74 minutes

Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes

Administration of chemotherapy into vein, 1 hour or less

Administration of chemotherapy into vein using push technique

Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg

Established patient office or other outpatient visit, 40-54 minutes

Injection of drug or substance into vein

Leuprolide acetate (for depot suspension), 7.5 mg

Hospital discharge day management, more than 30 minutes

Established patient office or other outpatient visit, 30-39 minutes

Administration of additional new drug or substance into vein, 1 hour or less

Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less

Administration of additional new drug or substance into vein using push technique

Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle

Infusion into a vein for hydration, 31-60 minutes

Established patient office or other outpatient visit, 20-29 minutes

Telephone medical discussion with physician, 11-20 minutes

Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less

Injection of additional new drug or substance into vein

Administration of chemotherapy into vein, each additional hour

Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle

Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg

Injection, pembrolizumab, 1 mg

Injection, daratumumab, 10 mg and hyaluronidase-fihj

Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg

Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes

Infusion into a vein for therapy, prevention, or diagnosis, each additional hour

Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion

Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg

Collection of blood sample from implanted device

Injection, hydrocortisone sodium succinate, up to 100 mg

Infusion into a vein for hydration, each additional hour

Cyclophosphamide, 100 mg

Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes

Injection, nivolumab, 1 mg

Injection of drug or substance under skin or into muscle

Injection, denosumab, 1 mg

Infusion, normal saline solution , 1000 cc

Infusion, normal saline solution, sterile (500 ml = 1 unit)

Injection, methylprednisolone sodium succinate, up to 125 mg

Injection, zoledronic acid, 1 mg

Injection, paclitaxel protein-bound particles, 1 mg

Injection, fulvestrant, 25 mg

Injection, diphenhydramine hcl, up to 50 mg

Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg

Injection, cisplatin, powder or solution, 10 mg

Injection, carboplatin, 50 mg

Injection, fluorouracil, 500 mg

Injection, irinotecan, 20 mg